TrialA Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
Trial details
- Registry ID
- NCT04395677
- Phase
- Phase 2
Drug research
AB-106
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as DS-6051b
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion GeneNCT04395677 | NUVB | Phase 2 | Active not recruiting | 2024-06-07Actual |
| Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene FusionNCT04617054 | NUVB | Phase 2 | Terminated | 2024-12-06Actual |
Phase II Study of AB-106 to Treat Patients With Solid Tumors With NTRK Gene Fusion
Trial details
- Registry ID
- NCT04617054
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |